Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (AXSM) Revenue
Annual & quarterly revenue history · segment & region breakdown
AXSM · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAxsome Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.71B, an increase of 65.55% year-over-year from $0.64B in FY2025.
Revenue trend
2025 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.64B | +$0.25B | +65.55% |
| 2024-12-31 | $0.39B | +$0.12B | +42.53% |
| 2023-12-31 | $0.27B | +$0.22B | +440.80% |
| 2022-12-31 | $0.05B | +$0.05B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare AXSM revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Axsome Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Axsome Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Axsome Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AXSM revenue · 4 questionsAXSM's trailing twelve-month (TTM) revenue is $0.71B. That is an increase of 65.55% year-over-year from $0.64B in FY2025.
▸ Source: FMP · Axsome Therapeutics, Inc. SEC filings · GAAP · Axsome Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026